Market research and planning numbers for the Heir Meds GLP-1 launch. Start with the landscape report, then use the growth model to test budgets and SEO targets.
Prepared for the Heir Meds team · Updated November 2, 2026
Executive summary
Heir Meds is entering a market that is large and growing but shifting fast away from the compounded-drug model it plans to lead with. The opening is care quality: the biggest brand has the worst reviews, and the best-reviewed platforms are small.
Two-tier market. Hims, Ro, LifeMD, Amazon and others now sell branded Wegovy, Zepbound and Foundayo at cash prices from about $149. Hims stopped advertising compounded GLP-1s in its March 2026 settlement with Novo. Novo and Lilly each work with about eight preferred telehealth partners; Heir Meds can still prescribe through their self-pay pharmacies, but without co-marketing.
Compounded risk is high and rising. The FDA sent 55 warning letters to telehealth firms in March and June 2026 and proposed ending bulk compounding of semaglutide and tirzepatide. A final rule is still pending. HHS's October 28 peptide policy eases compounding only for six wellness peptides, not GLP-1s. Good reviews are no shield: MEDVi (Trustpilot 4.4) received a warning letter and Eden reportedly did too.
Price position. Most compounded rivals charge $129–$249 a month all-in. Heir Meds' planned $199–$299 sits in the upper half, so the extra care must be visible.
Reviews are the weak spot of the leaders. Hims scores 3.0 on Trustpilot; Mochi, Henry Meds and Ivim score 4.4–4.9 by offering responsive clinicians and simple pricing.
Heir Meds starts at zero in search. Ro and Sesame win search with genuine health content, while Trimi’s hundreds of mass-produced comparison posts barely rank. Heir Meds needs a clinician-written content hub; by year two SEO patients could cost $34–$74 each versus $300 from paid ads.
Meta "GLP-1" attention is going to side-effect products. Supplements and apps for muscle, hair and nutrition run the top-reach ads. Building that support into the program is a creative and retention edge. Use real clinicians and patients in ads: MEDVi drew press scrutiny for apparently AI-generated ones.
Top actions: set the branded fallback gate, build a clinician-written SEO hub, and lead acquisition with Google Search and care-focused creative.
Market snapshot
Demand is huge and still growing, but 2026 turned GLP-1 telehealth into a two-tier market: platforms with branded-drug pharma deals, and everyone else selling compounded drugs under rising FDA pressure.
Platform market size: Fact.MR sizes GLP-1 telehealth platforms at $763.8M in 2026, rising to $3.28B by 2036 (15.7% CAGR). Cash-pay subscription is the largest revenue model and the US is the fastest-growing country (Fact.MR).
Branded prices fell: Novo cut cash-pay Wegovy and Ozempic from $499 to $349 a month for existing patients (eMarketer). Branded Wegovy pill now starts around $149 a month, close to compounded pricing.
Pharma picked partners: Novo's deals with Hims, Ro, LifeMD, GoodRx and Walgreens give those platforms preferred branded pricing; others must sell compounded or full-price branded drugs (FormBlends industry analysis). Novo and Lilly also bar their telehealth partners from offering compounded GLP-1s (eMarketer).
Oral GLP-1s arrived: The Wegovy pill and Lilly's Foundayo (orforglipron) launched in 2026. Foundayo added $184M to Lilly's latest quarter (24/7 Wall St.).
Retail giants entered: Walgreens launched GLP-1 telehealth in February 2026, and Amazon One Medical earned the top U.S. News rating (eMarketer, Advisory Board).
Consolidation: At least four smaller compounding-focused providers shut down or exited GLP-1s in Q1 2026, citing regulatory uncertainty and margin pressure (Telehealth Ally pricing report).
The new demand driver is support, not just access. A U.S. News survey of 1,251 GLP-1 patients (October 2026) found the greatest weight loss among patients with behavioral and psychological support (U.S. News).
Top 10 competitors
Hims & Hers and Ro dominate on scale; Mochi, Found and Henry Meds win on reviews. The ranking blends search visibility, scale, third-party ratings and momentum. Search traffic figures are in the SEO section below.
One to watch: Ivim Health claims a 4.9 Trustpilot rating on nearly 40,000 reviews and a U.S. News 4.0. GoodRx (22.5M monthly organic visits) is a traffic giant but mostly a price-comparison site; its weight-loss telehealth plan launched in late 2025 (eMarketer).
Coming up: Hims Q3 results on November 9, 2026 (Hims investor relations). Hims guided Q3 revenue to $880–$900M and raised full-year 2026 guidance to $3.1–$3.3B. In Q2 the move to branded GLP-1s lifted revenue per subscriber to $92 a month but cut gross margin from 76% to 64%, and Hims posted an $86.3M net loss (Hims Q2 2026 release). Its marketing spend rose 21.8% to $229.5M, faster than its 19% subscriber growth (Linkdot).
What to watch for Heir Meds:
Subscriber growth vs. ad spend. If Hims' cost per new subscriber keeps rising, expect Meta and Google auction prices to stay high; plan around the conservative CAC in the growth model.
Branded GLP-1 margins. A further margin drop would confirm that branded drugs earn far less than compounded ones, which matters for the compounded-vs-branded decision gate.
Any compounded or legal update. Hims still sells compounded GLP-1s "on a limited scale" and booked $47.5M in Q2 legal contingencies; new FDA or Novo action against it would signal tighter enforcement for everyone.
The leaders have moved to branded drugs plus a paid membership; the compounded-only players compete on low flat pricing and are the most exposed to regulation.
Wegovy pill and pen, Ozempic, Zepbound, Mounjaro; membership billed separately. Also hair, sexual health, hormones, labs.
Scale (2.891M subscribers, Q2 revenue $753.2M, up 38%) (Subscription Insider). Biggest Meta advertiser in the category: ~1,341 active ads reaching ~58M people in 30 days (TrendTrack).
Lowest review score of the majors (Trustpilot 3.0). Settled with Novo on March 9, 2026: stopped advertising compounded GLP-1s, limited to clinical necessity; Novo can refile (American Med Spa Assn.). Was referred to DOJ by HHS (Telehealth.org).
Ro Body membership + Wegovy, Zepbound, Foundayo; insurance concierge.
Strong content SEO (weight-loss, pricing, Zepbound and dosing pages each draw 17K–88K visits a month). Best customer-satisfaction score from U.S. News.
Separate membership makes total cost high; BBB "B" rating with billing and cancellation complaints (GLP1 Clinics).
The second tier splits into three camps: compounded sellers with strong reviews but heavy regulatory exposure (Ivim, Remedy, MEDVi, Eden, Trimi), insurance-first generalists (PlushCare, Sesame, Zealthy), and premium coaching programs (Calibrate). The manufacturers themselves (LillyDirect, NovoCare) now set the price floor for branded drugs.
FDA warning letter Feb 20, 2026; scrutiny over apparently AI-generated doctors and patients in ads; reported on track for ~$1.8B 2026 sales (Drug Discovery Trends)
Not a clinic but the price floor every branded seller must match
Organic traffic: Search Atlas US estimates, latest month available (Oct 30, 2026 pull).
What the wider set adds:
Pharma partner lists are now a moat. Novo's telehealth partners include Ro, LifeMD, GoodRx Care, WeightWatchers, knownwell, Hims, eMed and Costco/Sesame; LillyDirect's include Ro, LifeMD, Teladoc, Noom, Form Health, knownwell, WeightWatchers and Hims (MatchGLP1). A non-partner can still prescribe to LillyDirect or NovoCare self-pay, but without co-marketing.
High reviews do not protect compounded sellers from the FDA. MEDVi (4.4) and Eden both drew warning letters this year; Ivim and Remedy rate 4.6–4.9 but carry the same exposure.
AI-generated marketing is now a news story. MEDVi's apparent AI-made doctors and patients drew press scrutiny. Use real clinicians and real patients with consent.
Mass-produced comparison content does not rank. Trimi publishes hundreds of "X vs Trimi" posts yet gets almost no organic traffic; Sesame ranks well with genuine health content. Heir Meds' content hub should be clinician-written, not volume-written.
Retatrutide is a red line. Some sellers already offer this unapproved Lilly trial drug; doing so invites FDA action.
Pricing benchmark
Most compounded rivals charge $129–$249 a month all-in, so Heir Meds' planned $199–$299 lands in the upper half of the compounded market and level with branded Wegovy-pill plans.
Published prices compiled from provider pages and review sites, Feb–Jul 2026; promos excluded
Branded is now price-competitive. The Wegovy pill and Foundayo start at about $149 cash; with membership the total is $174 (Amazon) to about $298 (Hims, Ro month-to-month) (Briefs, RX Index, GLP1 Clinics).
Compounded tirzepatide runs higher: $278 at Mochi, about $349 at Henry Meds, $240–$359 at Fridays (RX Index, Telehealth Ally, MatchGLP1).
Intro hooks are standard: $39 first-month memberships (Ro, Mochi, Hims), and prepaid 6–12 month plans for the lowest rate.
Budget entrants such as Trimi advertise $99–$125 all-in, pulling the floor down (Trimi).
Caveat: many price figures come from comparison sites, some run by competitors, and prices change monthly. Verify each competitor's live checkout before setting final prices.
SEO and search landscape
Heir Meds has no organic search presence yet; the leaders win search with education content, not their homepages.
Search Atlas Site Explorer, US organic estimates pulled Oct 30, 2026; months vary by domain
How the leaders win search:
Ro builds a content hub. Beyond its homepage, its top pages are the weight-loss hub (~88K visits a month), a calorie-deficit calculator (~24K), retatrutide dosing (~20K), Zepbound (~20K), pricing (~18K) and tirzepatide dosage (~18K). About 45% of its organic traffic is non-branded.
Hims and Ro dominate AI answers. Each appears in Google AI Overviews for roughly 34,000–35,000 keywords; most smaller rivals appear in under 1,000.
Mochi and WeightWatchers live on brand searches. About 70% of Mochi's and 85% of WeightWatchers' organic traffic comes from people already searching their name.
Henry Meds is the reverse: about 96% of its smaller traffic is non-branded, showing a small site can still capture high-intent searches.
Upcoming drugs pull traffic. Ro already ranks #8 for "retatrutide," a drug not yet approved, by publishing dosing and explainer content early.
Heir Meds baseline (heirmeds.co): 0 estimated organic visits and 4 ranked keywords as of September 2026. The next step is a GLP-1 content hub (pricing, dosing, side effects, compounded vs branded, oral options) with clinician bylines.
Paid media and creative
Hims outspends everyone on Meta by a wide margin, and most "GLP-1" ads on Meta now come from companion products, not prescribers.
Who is running Meta ads (TrendTrack, October 2026):
Advertiser
Active Meta ads
30-day reach
What they push
Hims
~1,341
~57.8M
Branded GLP-1s across Hims and Hers, plus other categories
Noom
~564
~0.9M
GLP-1 microdose landing page
Fridays
~98
Not reported
Lifestyle video creative
Mochi Health, Henry Meds
No ads matched in the library
—
Appear to lean on search, referral and reviews
What the top "GLP-1" ads are selling. Of the 20 highest-reach US Meta ads mentioning GLP-1 since August 2026, none were from a prescriber. They came from:
Side-effect supplements: muscle loss, hair thinning and nutrient gaps on GLP-1s (IM8, Bloom & Bond, JSHealth).
Tracking apps: dose, protein and water logging (Shotsy, MeAgain).
Fitness and education: iFIT GLP-1 plans, a MasterClass on GLP-1s.
Two reasons stand out. Prescribers must pass LegitScript and Meta's healthcare checks, and the FDA has penalized ad copy that implies compounded drugs equal branded ones (see Regulatory). So prescribers keep "GLP-1" and drug names out of copy and sell outcomes, price and care instead.
Real-person testimonial video over polished brand spots.
Price-anchored offers: "$39 first month," "from $149."
Microdosing and maintenance for people who are not obese.
These themes point to an opening for Heir Meds: build side-effect care (protein, muscle, hair) into the program and lead with it in creative.
Reviews and reputation
Review scores track care quality and billing honesty, not size: the biggest brand has the weakest score, and the best-reviewed platforms answer every complaint.
Platform
Trustpilot
Other signals
Ivim Health
4.9 (~40K)
U.S. News 4.0
Mochi Health
4.4 (~16.2K)
U.S. News 4.4
Henry Meds
4.4 (~12.5K)
Replies to 100% of negative reviews, usually within 24 hours (Trustpilot)
What patients complain about (recurring in Hims, Ro and Fridays reviews):
Billing after cancellation, or charges on expired cards.
Non-refundable prepaid plans and memberships.
Lost or late shipments with slow replacement.
Clinicians who don't engage with messages ("just tell them what they want to hear").
Advertised price far below the real total once membership is added.
What patients praise (Mochi, Henry Meds, Ivim): a named provider who listens, fast replies, simple flat pricing, and steady results.
Why patients switch platforms: the top reason in the U.S. News survey was that the medication did not produce weight loss (28%) (U.S. News). Dose titration and follow-up are therefore a retention lever, not just a clinical one.
Regulatory and risk watch
Compounded semaglutide and tirzepatide are legal in 2026 only as patient-specific prescriptions with a documented clinical reason, and the FDA is actively enforcing both that rule and how compounded drugs are marketed. This is the single biggest risk to a compounded-first launch.
The rule today. The shortages ended (tirzepatide December 2024, semaglutide February 2025). A 503A pharmacy may compound only when the prescriber documents a significant difference for that patient, and the product must not be "essentially a copy" of Wegovy or Zepbound (Rehabilitation Health, Oct 2026, PeptideAI policy summary). Salt forms (semaglutide sodium or acetate) are not allowed, and adding B12 may not get a product out of the "copy" category.
Date
Event
Why it matters
Oct 28, 2026
HHS issues an interim enforcement-discretion policy letting 503A pharmacies compound six unapproved peptides (BPC-157, TB-500, epitalon, KPV, MOTS-c, Semax); comments open through Nov 13 (NBC News, CBS News)
Opens a wellness-peptide category, but does not loosen GLP-1 rules
Oct 2026 (pending)
No final decision yet on keeping GLP-1s off the 503B bulks list
A final rule would end large-scale compounding for good
June 16, 2026
FDA sends 25 warning letters to telehealth firms over compounded GLP-1 claims (Mondaq)
Enforcement is continuing every few months
May 31, 2026
FDA counts 990 adverse-event reports for compounded semaglutide and 730+ for tirzepatide (PeptideAI)
Safety narrative strengthens the case against compounding
May 1, 2026
FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list (Pharmacy Times)
Outsourcing-facility supply would be closed even in a future shortage
Mar 9, 2026
Novo and Hims settle: Hims stops advertising compounded GLP-1s, sells branded Wegovy and Ozempic (American Med Spa Assn.)
Sets the template: pharma will trade branded access for an end to compounded marketing
Mar 3, 2026
FDA sends 30 warning letters to telehealth firms (Venable)
Cited: implying sameness to approved drugs, and private-label branding that hides the real compounder
Feb 2026
HHS refers Hims to the DOJ after its $49 compounded Wegovy-pill launch (Telehealth.org)
Platforms are under pressure to block compounded ads
Latest: the October 28 peptide policy. HHS Secretary Kennedy said regulators will not act against licensed pharmacies or physicians that compound six unapproved peptides while the FDA works on a formal rule (NBC News). The policy requires patient-specific prescriptions, an FDA-registered ingredient maker, a lab certificate for raw ingredients, quality testing and reporting of serious side effects (CBS News). It is a draft open to comment through November 13 and stays in place until the FDA finalizes a rule, which the FDA has not yet proposed.
Update, Nov 2: The policy was published in the Federal Register on October 30, and law-firm summaries now give the detail (Arnold & Porter, Foley):
503A pharmacies and licensed physicians only. 503B outsourcing facilities are not covered, so supply stays small-batch and patient-specific.
Ten conditions must all be met, including: ingredients from an FDA-registered, cGMP manufacturer with a certificate of analysis naming the factory; one active ingredient per product; only the listed routes (e.g. injection, nasal); human bioavailability data for any oral form; the label line "This is a compounded drug product. Not for resale"; and serious side effects reported to FDA MedWatch and to each state the product ships to.
No protection beyond HHS's word. The policy does not change the law, does not bind state pharmacy or medical boards, and HHS can withdraw it without notice. Private lawsuits and state action remain possible.
Opposition is organized. The Partnership for Safe Medicines has filed a citizen petition asking FDA to reject this approach, and FDA's drug center had recommended against listing these peptides.
Comments close November 13, 2026. Watch for changes to the conditions after that date.
If Heir Meds explores a peptide line, first confirm that its prescribers and the pharmacy partner meet every condition, and check each target state's board rules; the policy says nothing about telehealth prescribing or advertising.
What it means for Heir Meds:
No change for GLP-1s. The policy covers only peptides that are not part of an FDA-approved drug, so semaglutide and tirzepatide stay under the stricter rules above. Retatrutide is not on the list either; it remains an unapproved trial drug, and a CBS lab test of a store-bought sample found no peptide in it.
A possible add-on line. BPC-157, TB-500 and the others appeal to the same wellness and longevity audience as GLP-1s. Heir Meds could offer them through its provider group and a 503A pharmacy that meets the sourcing and testing conditions.
High risk if rushed. The peptides remain unapproved with no FDA review of safety or efficacy; FDA scientists advised against the change, and critics call it a shortcut (Rolling Out). The policy could change after comments or under a future administration. Make no health claims, expect Meta and Google to block peptide ads, and get counsel's sign-off before launching any peptide offer.
The broader signal: this administration favors access through compounding for non-approved peptides while still cracking down on compounded copies of approved GLP-1 drugs.
Ad platform rules. Google requires LegitScript certification for prescription-drug and telehealth ads. Meta requires authorization and restricts compounded GLP-1 ads in most contexts. TikTok bans prescription and telehealth ads outright (AuditSocials, CareValidate).
What this means for Heir Meds:
Name the compounding pharmacy on product pages and labels; do not present Heir Meds as the maker.
Remove any copy that says or implies "same as Wegovy/Zepbound," "generic," or "FDA-approved" for compounded drugs.
Confirm the pharmacy does not use salt-form or research-grade API.
This is a summary, not legal advice; a healthcare regulatory attorney should sign off before launch.
Recommendations for the Heir Meds launch
Win on care quality and honesty in the gap between cheap async compounded sellers and expensive branded memberships, and add a branded option before regulation forces the issue.
1. Position on care, not price. The best-reviewed platforms (Mochi, Ivim, Henry Meds) win on a named clinician who responds fast and simple pricing. Promise a named provider, a dietitian, a reply within 24 hours, and a dose-adjustment check-in. Build in side-effect support for muscle, protein and hair, since that is what GLP-1 buyers are clicking on in Meta ads.
2. Make the $199–$299 price visibly worth it. Heir Meds sits above most compounded rivals, so the extra value must be obvious on the pricing page.
Show one all-in monthly price with the membership included, flat across doses.
Use a first-month hook ($39–$99 is market standard) but avoid non-refundable prepaid traps, the top complaint against Hims and Ro.
Offer one-click cancellation and spell out refund terms.
3. Set a decision gate on compounded versus branded. Launch compounded only with complete medical-necessity documentation, and line up branded oral options (Wegovy pill, Foundayo at about $149 cash) as the fallback.
Gate
Trigger to watch
Action
Pre-launch
Medical-necessity documentation not complete for every compounded Rx
Hold compounded scale-up; launch with a waitlist or branded only
Any time
FDA finalizes the 503B bulks exclusion, or a warning letter names Heir Meds or its pharmacy
Shift new patients to branded within 30 days
Day 60
Meta or Google rejecting compounded-drug ads, or CAC too high to profit at $199
Lead acquisition with branded oral offers
Day 90
Branded share of new patients and margin per patient
Decide the long-term mix
4. Spend the $100K–$500K where rivals are thin.
Google Search first: LegitScript is done, so target high-intent non-branded terms ("GLP-1 doctor online," "tirzepatide cost," "oral Wegovy price").
Meta: sell outcomes, care and side-effect support; keep compounded-drug claims and branded drug names out of compounded ads.
Creators and patient stories: with FTC disclosures and no efficacy claims for compounded drugs.
Skip TikTok paid: it bans telehealth and prescription ads; use organic only.
SEO from day one: a content hub modeled on Ro's (pricing, dosing, oral options, side effects, upcoming drugs like retatrutide).
5. Build reviews from patient one. Invite every patient to Trustpilot after their first delivery and reply to every negative review within 24 hours, as Henry Meds does. Reviews are how small brands beat Hims (3.0).
Growth model and budget scenarios
At a $300 CAC, $100K of paid media should bring in about 333 paying patients and roughly $131K of profit after ad spend in 12 months, paying back in month 4. The interactive Heir Meds Growth Model lets the team change every assumption and see paid and SEO results update live.
Budget
CAC $425 (conservative)
CAC $300 (base)
CAC $200 (optimistic)
$25K
59 patients · +$16K
83 patients · +$33K
125 patients · +$62K
$100K
235 patients · +$63K
333 patients · +$131K
500 patients · +$247K
Assumptions: $249/month price, $115/month cost per patient (medication, provider, shipping, support) plus 3.5% card fees, 15% of patients cancelling each month, spend spread over 3 months. Profit is 12-month gross profit minus ad spend. Excludes agency fees and refunds.
Retention is the biggest lever. Cutting monthly cancellations from 15% to 10% raises profit more than lowering CAC by $100.
SEO builds slowly. A new domain sees little traffic before month 4; the model projects organic visits and patients by keyword using Search Atlas volumes and 2026 click rates by Google position.
Replace the cost defaults with real pharmacy and provider quotes before using these numbers for budgeting.
Why SEO is the long-term growth engine
Paid ads rent patients; SEO builds an asset that keeps bringing them in. In the growth model's base case, a $5,000-a-month SEO program costs about $95 per patient in year one and about $34 in year two, against $300 for a paid patient. Even in the conservative case, year-two SEO patients cost about $74, a quarter of the paid CAC.
Paid ads (base CAC)
SEO, conservative
SEO, base
Cost per new patient, year 1
$300
about $210
$95
Cost per new patient, year 2
$300 or more
$74
$34
New patients a month at month 12
Stops when spend stops
~67
~148
Organic visits a month at month 12
—
~5,400
~14,300
Figures come from the Heir Meds Growth Model: $60K a year of SEO spend, 25 target keywords, 2026 click rates by Google position, $249 price, 15% monthly cancellations. Year 2 assumes month-12 rankings hold and spend stays at $5K a month.
Why it matters for Heir Meds specifically:
Paid costs are rising for everyone. Hims grew marketing spend 21.8% in Q2 but subscribers only 19%, so each new patient got more expensive. GLP-1 CAC benchmarks have climbed to $250–$450 for new entrants. SEO is the only major channel whose cost per patient falls over time.
Ad platforms can shut off; search rankings can't. Meta and Google restrict compounded GLP-1 ads, state attorneys general are pressing Meta to tighten further, and TikTok bans telehealth ads outright. A ranking page keeps working if an ad account is paused.
The value compounds. In the base case, SEO patients going into year two equal roughly $530K of paid media a year at today's CAC, for $60K of SEO spend.
Searchers arrive with intent. Someone typing "compounded tirzepatide" or "tirzepatide online" is already shopping. These buying terms convert several times better than social ad clicks.
AI answers reward expert content. Google's AI Overviews now take many clicks from plain listings, but pages cited inside them earn more clicks. Clinician-written, well-sourced pages are what gets cited.
Where the opportunity is (Search Atlas, US monthly searches):
Low difficulty, high value: "compounded tirzepatide" (40,500 searches, difficulty 20), "tirzepatide dosage chart" (33,100, difficulty 30), "semaglutide dosage chart" (8,100, difficulty 38), "microdosing semaglutide" (3,600, difficulty 33). A new site can realistically reach the top five for these within a year.
Big volume, longer play: "semaglutide vs tirzepatide" (60,500), "weight loss injections" (110,000), "GLP-1 side effects" (135,000). Harder to win, but they build the authority that lifts the buying pages.
Side-effect content doubles as differentiation. Muscle loss, hair loss and protein are what GLP-1 users are clicking on in ads, and they fit Heir Meds' care-quality positioning.
Risks to plan for:
Concentration. About half the base-case SEO patients come from ranking #3 for "compounded tirzepatide." If compounded drugs are restricted further, that page must pivot to branded and oral options, so build it around the patient's question, not one product.
Time. A new domain sees little before month 4, so SEO cannot replace launch ads; it lowers blended CAC from year two.
Compliance. Pages about compounded drugs must not claim they are the same as Wegovy or Zepbound, and must name the compounding pharmacy.
Recommended SEO plan for the first 12 months:
Month 0–1: fix technical SEO, set up Search Console and rank tracking for the 25 target keywords.
Month 1–3: publish the buying and price pages (compounded tirzepatide, semaglutide and tirzepatide pricing, oral Wegovy and Foundayo options) with clinician bylines.
Month 2–6: publish dosage charts, semaglutide vs tirzepatide, microdosing and side-effect guides; earn links from health publishers and patient communities.
Month 6–12: refresh pages monthly with current prices, track AI Overview citations, and expand into maintenance and "after GLP-1" topics.
Every quarter: compare actual rankings and SEO-sourced patients against the growth model and adjust spend.
Methodology and sources
Data pulled October 30, 2026. Organic traffic comes from Search Atlas Site Explorer (US Google organic estimates only; paid, app, direct and social traffic are excluded, and the latest month varies by domain). Meta ad counts and reach come from TrendTrack. Prices come from provider pages as reported by comparison sites, several of which are run by competitors (Trimi, FormBlends); treat them as directional and verify at checkout. Review figures come from Trustpilot pages and published comparisons. Nothing here is legal advice.
Move the sliders to see what a paid budget and a 12-month SEO program could return. Every default is a published 2026 benchmark, listed at the bottom. These are planning estimates, not forecasts.
Patients acquired = ad spend ÷ CAC. Each patient pays monthly until they cancel. Profit is counted over 12 months from launch.
Total ad budget
Cost to acquire a paying patient (CAC)
2026 benchmarks for GLP-1: $150–$250 (mature brands) to $250–$450 (new entrants).
Cost per patient per month
Plus 3.5% card processing. Replace with real pharmacy and provider quotes.
Cash position by month
Cumulative profit after ad spendActive patients (right axis)
Scenario grid · 12-month profit after ad spend
Uses your price, costs and cancellation rate. Spend spread over the months set above.
Sanity check: what CAC does a Google search funnel imply?
Your target keywords cost $10–$48 a click (Search Atlas, Oct 2026): "compounded tirzepatide" $17, "semaglutide online" $48.
2 · SEO: where 12 months of content could land
Set the Google position you expect each page to reach by month 12. Visits = monthly searches × click rate for that position × long-tail factor. Rankings ramp up slowly; a new domain usually sees little before month 4.
Clinician-written content, technical SEO, link building.
A page that ranks for its main term also gets traffic from related phrases.
Lower it if AI Overviews take more clicks on your terms.
Visitor → paying patient, by page type
Percent of visitors. Buying pages convert best; side-effect readers mostly already have a prescriber.
Organic visits and new patients by month
Organic visitsNew paying patients (right axis)
Target keywords · US monthly searches (Search Atlas, Oct 2026)
Difficulty is 0–100; above 70 is hard for a new site within a year. Compounded-drug pages must not claim sameness to Wegovy or Zepbound.
3 · Month 12 together
Paid and SEO patients combined, using the settings above.